Skip to Content
Find More Like This
Return to Search

Carriers for Plasmid and RNP Delivery in the Treatment of Cancer and Other Disease States

United States Patent Application

View the Complete Application at the US Patent & Trademark Office
Sandia National Laboratories - Visit the Intellectual Property Management and Licensing Website
The present disclosure relates to the delivery of polynucleotides and/or oligonucleotides using silica delivery platforms, e.g., silica carriers or protocells. In particular, in the present disclosure, polynucleotides in the form of plasmids expressing siRNA may be administered as cargo in the silica delivery platform to a patient or subject to inhibit and/or treat cancer in a patient. In one aspect, the silica delivery platform that have been charged with cargo comprising plasmid DNA (in particular, CRISPR ds plasmid DNA) which expresses siRNA, shRNA, mRNA and other RNA which may be used to administer these plasmids to patients in order to effect inhibition of cancer cells (especially including apoptosis of those cancer cells) and effective and/or prophylaxis of cancer, as well as numerous pathogens, including viruses, bacteria, fungi, and/or other disease states and/or conditions. In another aspect, the silica delivery platform comprises a biological package (e.g., plasmid nucleic acid, such as a for a CRISPR/Cas system) that interacts with a genomic sequence to either activate or inhibit gene expression. Such vehicles can be employed to control gene activation and repression in a host (e.g., a patient) and/or a pathogen.
Brinker, Charles Jeffrey (Albuquerque, NM), Carnes, Eric C. (Albuquerque, NM), Ashley, Carlee Erin (Albuquerque, NM), Santarpia, Joshua (Albuquerque, NM), Greene, Adrienne Celeste (Albuquerque, NM), Negrete, Oscar (Pleasanton, CA), Branda, Steven (Livermore, CA), Muniz, Ayse (Albuquerque, NM), Agola, Jacob Ongundi (Albuquerque, NM), Butler, Kimberly (Albuquerque, NM)
15/ 474,810
March 30, 2017
GRANT SUPPORT [0002] This invention was made with government support under DE-AC04-94AL85000, awarded by the Department of Energy, U01 CA151792, awarded by the National Cancer Institute and EY016570, awarded by the National Institutes of Health. The government has certain rights in the invention.